Table 2.
Clinical summary of the test cohort
| Diagnosis | N | ∅ age at surgery | ∅ age at onset | ∅ duration | Sex (female/male) |
|---|---|---|---|---|---|
| FCD 1A | 2 | 10.5 (± 12.0) | 4.5 (± 6.4) | 6.0 (± 5.7) | 1/1 |
| FCD 2A | 6 | 20.9 (± 18.7) | 4.4 (± 3.4) | 16.2 (± 15.4) | 1/5 |
| FCD 2B | 6 | 22.8 (± 12.5) | 6.6 (± 6.1) | 16.8 (± 13.1) | 0/6 |
| FCD 3A | 4 | 20.3 (± 18.9) | 3.8 (± 4.3) | 16.5 (± 19.7) | 2/2 |
| FCD 3C | 6 | 23.3 (± 18.1) | 14.2 (± 12.5) | 9.9 (± 8.7) | 3/3 |
| FCD 3D | 2 | 27.0 (± 14.1) | 2.5 (± 3.5) | 24.5 (± 17.7) | 0/2 |
| mMCD | 5 | 29.0 (± 13.8) | 17.0 (± 8.9) | 13.0 (± 3.2) | 2/3 |
| MOGHE | 5 | 9.7 (± 10.4) | 5.0 (± 8.4) | 4.7 (± 2.8) | 1/4 |
| TLE | 3 | 37.3 (± 9.9) | 17.0 (± 11.4) | 20.3 (± 2.9) | 0/3 |
| TSC | 4 | 3.6 (± 1.9) | 0.0 (± 0.0) | 3.6 (± 1.9) | 2/2 |
FCD focal cortical dysplasia, mMCD mild malformation of cortical development, MOGHE mMCD with oligodendroglial hyperplasia in epilepsy, TLE temporal lobe epilepsy, TSC– tuberous sclerosis complex